预约演示

更新于：2026-02-05

Dexamethasone Sodium Phosphate

地塞米松磷酸钠

更新于：2026-02-05

概要

基本信息

药物类型

小分子化药

别名

Dex 21-P、Dexamethasone 21-Phosphate、eDSP

+ [23]

靶点

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [10]

在研适应症

脑水肿新型冠状病毒感染急性呼吸窘迫综合征+ [38]

非在研适应症

过敏反应白内障干眼综合征+ [16]

原研机构

Merck & Co., Inc.

在研机构

AVM Biotechnology LLCWockhardt UK Ltd.

Hameln pharma Gmbh.

+ [8]

非在研机构

Scilex Pharmaceuticals, Inc.

Mercator MedSystems, Inc.

Aspen Global, Inc.

+ [5]

权益机构

台湾微脂体股份有限公司

Bausch Health Cos., Inc.

Endo International Plc

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1959-08-26)

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C22H30FNaO8P

InChIKeyVIKBYTWZYXGHAT-WKSAPEMMSA-N

CAS号2392-39-4

关联

2,712

项与地塞米松磷酸钠相关的临床试验

NCT04366115

/ Not yet recruiting临床1期

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

开始日期2026-12-01

申办/合作机构

AVM Biotechnology LLC

[+1]

NCT07343817

/ Not yet recruiting早期临床1期IIT

Ultrasonic Evaluation of Metoclopramide With or Without Dexamethasone on Gastric Motility in Traumatic Patients

Reflux and the aspiration of gastric contents have always been important focal points. Previous study stated that trauma is an important factor in aspiration pneumonia.
Often, emergency trauma patients have residual gastric contents due to the ingestion of food before injury, the accidental swallowing of nasal and/or oral blood after injury, and delayed gastric emptying due to stress, pain, or the use of opioids.
During sedation or general anesthesia, such satiated patients are often at risk of aspiration due to a reduction in lower esophageal sphincter tension and the protective inhibition of the airway reflex.
Perioperative gastric ultrasound can be performed at a bedside ultrasound unit; it can safely, non-invasively, conveniently, and effectively evaluate the fullness of a patient's stomach and the nature of their gastric contents.
It can also be used in the selection of an appropriate method for the anesthetic induction process and can reduce the risk of vomiting, aspiration, and related complications.
As a gastric motility-promoting drug, metoclopramide can accelerate gastric emptying.
Dexamethasone reduced the incidence of nausea and vomiting and improve gastric motility.

开始日期2026-07-01

申办/合作机构

Assiut University

[+1]

NCT07341867

/ Not yet recruiting临床1期IIT

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype.
Study Drugs Include:
* Daratumumab
* lenalidomide
* bortezomib
* dexamethasone
* carboplatin
* paclitaxel
* pembrolizumab
* cyclophosphamide
* doxorubicin

开始日期2026-06-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

100 项与地塞米松磷酸钠相关的临床结果

登录后查看更多信息

100 项与地塞米松磷酸钠相关的转化医学

登录后查看更多信息

100 项与地塞米松磷酸钠相关的专利（医药）

登录后查看更多信息

1,829

项与地塞米松磷酸钠相关的文献（医药）

2026-01-01·Orthopaedic Journal of Sports Medicine

Regional Anesthesia Utilizing Liposomal Bupivacaine, With or Without Dexamethasone, Provides Excellent Pain Control and Minimizes Opioid Consumption Following Anterior Cruciate Ligament Reconstruction

Article

作者: Ciccotti, Michael G. ; Voskeridjian, Armen ; Dodson, Christopher C. ; Johns, William L. ; Muchintala, Rahul ; Miltenberg, Benjamin ; Salvo, John ; Cohen, Steven B. ; Hammoud, Sommer ; Sherman, Matthew

Background::

Perioperative nerve blocks are commonly used for regional analgesia with anterior cruciate ligament (ACL) reconstruction (ACLR). Liposomal bupivacaine (LB) is a long-acting anesthetic agent providing up to 72 hours of nerve blockade. It is theorized that the addition of dexamethasone to LB (LB+dex) may prolong the analgesic duration.

Purpose::

To characterize pain control and opioid consumption with adductor canal block (ACB), interspace between the popliteal artery and capsule of the posterior knee (iPACK), and suprasartorial infiltration (SSI) regional anesthetic techniques utilizing LB after ACLR and to compare LB versus LB+dex.

Study Design::

Randomized controlled trial; Level of evidence, 1.

Methods::

Patients undergoing primary ACLR using bone–patellar tendon–bone or quadriceps tendon autograft were included. All patients received an ACB, iPACK, and SSI preoperatively. Patients were randomized to receive either LB or LB+dex for their anesthetic agent. Opioid consumption, visual analog scale (VAS) scores, pain control satisfaction, and duration of block effect were recorded postoperatively.

Results::

A total of 131 patients were included in the analysis. The mean opioid consumption for all patients was 1.20 ± 2.42 five-mg oxycodone tablets (8.97 ± 18.12 morphine milliequivalents [MME]). We did not observe a significant difference in oxycodone consumption between cohorts during the study period (1.42 ± 2.92 vs 0.97 ± 1.91; 10.65 ± 21.90 MME vs 7.28 ± 14.33 MME; P = .76). An estimated 95.2% of opioids prescribed went unused and 77.1% (101/131) of patients consumed no opioids. There was no significant difference in VAS score, patient satisfaction, or duration of block effect between cohorts.

Conclusion::

A single shot of LB with or without dexamethasone via ACB, SSI, and iPACK block provided excellent pain control and minimized opioid consumption after autograft ACLR. Nearly 80% of patients did not require opioids postoperatively, making opioid-free ACLR a realistic possibility for many patients. When narcotics were required, the dose of opioids was minimal; patients required 1.2 tablets of oxycodone on average, and >95% of the opioids prescribed went unused. Despite previous reports suggesting a prolonged duration of anesthetic effect when LB is combined with dexamethasone, we found no difference in opioid consumption, VAS score, patient satisfaction, or duration of block effect when patients received dexamethasone with their regional block. The utilization of regional anesthetic techniques such as ACB, SSI, and iPACK blocks in conjunction with LB-based anesthetics could allow providers to curtail or potentially eliminate opioid prescriptions after ACL surgery.

Registration::

NCT06006624 (ClinicalTrials.gov identifier).

2025-12-01·VETERINARY DERMATOLOGY

Chemical Stability of Ceftazidime Compounded in Saline, Glycerin and Dexamethasone‐ SP Solutions Stored at −20°C, 4°C and 25°C Over a 60 Day Period

Article

作者: Tsai, Will ; Gustafson, Daniel ; Daniels, Joshua B. ; Hoppers, Sarrah ; Banks, Krista ; Bachtel, Jeremy ; Snidow, McKenna

ABSTRACT:

Background:

Chronic cases of canine otitis externa (OE) often develop infections with Pseudomonas aeruginosa (PA). Given the organism's high level of resistance, veterinary surgeons often turn to compounded solutions. Limited data describing the stability and potency of compounded ceftazidime (CAZ) solutions are available, which may affect clinical outcome.

Hypothesis/Objectives:

To evaluate the chemical stability of compounded glycerin (GLY) and dexamethasone sodium phosphate (DEX‐SP) CAZ solutions in three different storage temperatures over a 60‐day period. Based on previous evaluations, CAZ concentrations would decrease with increased temperature and time.

Materials and Methods:

Ceftazidime was compounded at 10 mg/mL with 100 mL 0.9% sodium chloride (NA + CAZ), 100 mL glycerin +0.9% sodium chloride (GLY + CAZ) and 100 mL dexamethasone sodium phosphate +0.9% sodium chloride (DEX‐SP + CAZ), stored at −20°C, 4°C and 25°C for 60 days. Mass spectrometry was used to analyse CAZ stability at specific time points (Day[D]0, D7, D14, D28, D60).

Results:

Chemical stability of CAZ concentrations was affected by storage time, temperature and diluent. CAZ concentrations decreased over time with increased temperature; frozen CAZ concentrations remained stable over time for all solutions.

Conclusions and Clinical Relevance:

Compounded CAZ stability varies by diluent, storage temperature and storage duration. NA + CAZ and DEX‐SP + CAZ solutions are stable for ≤ 28 days refrigerated and retain potency for ≥ 60 days if stored frozen. These solutions offer alternative options for treatment of PA OE.

2025-11-01·CPT-Pharmacometrics & Systems Pharmacology

Population Pharmacokinetic Modeling and Pediatric Exposure of Dexamethasone Sodium Phosphate Encapsulated in Erythrocytes (eDSP) Administered Monthly for Treatment of Neurological Symptoms of Patients With Ataxia Telangiectasia

Article

作者: Kheibarshekan, Leila ; Mambrini, Giovanni ; Tremblay, Pierre‐Olivier ; Ozdin, Deniz

ABSTRACT:

The EryDex System (EDS) is a drug/device combination, which has been tested in clinical trials for ataxia telangiectasia (AT). EDS encapsulates dexamethasone sodium phosphate (DSP) solution in autologous erythrocytes at the point of care, and encapsulated DSP (eDSP) is infused back into the patient. Low doses of dexamethasone are released from erythrocytes over a 30‐day period. This study aimed to (1) characterize the pharmacokinetics (PK) of dexamethasone released from intravenously infused eDSP based on data collected in clinical trials of healthy adults and pediatric AT patients, and to (2) simulate and extrapolate exposure measures of dexamethasone following intravenous infusion of eDSP administered once per month over 6 months in a pediatric population. The population PK model was developed using dense PK data from a phase 1 study in healthy adults and sparse PK data from a phase 3 study in pediatric AT patients. Three dose levels were studied, and the overall PK population included 24 healthy adults and 109 AT patients. The PK of dexamethasone released from eDSP was described using a simplified two‐compartment model, adequate for estimating systemic exposure despite not fully capturing RBC release kinetics indicative of a triphasic pattern. The model showed a good fit, and future refinement will include mechanistic release modeling as more in vitro and in vivo data become available. Monte Carlo simulations of eDSP showed a rapid peak at 0.67 h, followed by sustained dexamethasone release; faster in the first 24 h, then slower over 20–30 days. No accumulation occurred with once‐monthly dosing.

448

项与地塞米松磷酸钠相关的新闻（医药）

2026-01-30

·FiercePharma

Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease

Quince Therapeutics will cease clinical development of eDSP and “[i]ntends to preserve cash and explore available options,” the company said in a Jan. 29 release. Quince Therapeutics’ novel method of delivering steroids in a patient’s own red blood cells has turned out to be a bust in ataxia-telangiectasia (A-T), a rare inherited disorder.A pivotal phase 3 trial of the company’s lead asset, dexamethasone-containing eDSP, has failed to meet both its primary and secondary endpoints, Quince said late this week. The company’s stock price on Nasdaq plummeted more than 90% on the news, closing at $0.27 per share Thursday.Quince will cease clinical development of eDSP and “[i]ntends to preserve cash and explore available options,” the company said in a Jan. 29 release.As of the end of September, Quince had cash, cash equivalents and short-term investments of $26.3 million, which the company expected could support its operations into the second quarter of 2026, according to its third-quarter report. A-T, also known as Louis-Bar syndrome, is a rare genetic disease that affects the nervous system and the immune system. Caused by mutations in the ATM gene, the disease begins in early childhood with the first signs being unsteady movements and poor coordination (ataxia). Another main characteristic of the condition is small clusters of dilated blood vessels in the eyes and on the skin (telangiectasia). Most patients with the condition live up to 30 years of age as infections and cancer develop. Citing IQVIA data, Quince noted that about 4,600 patients are diagnosed with A-T in the U.S.No approved therapeutic treatments currently exist for A-T. Corticosteroids such as dexamethasone have shown some benefits in improving neurological functioning in A-T, but their long-term use is limited by toxicity.Quince developed eDSP, also known as EryDex, using its autologous intracellular drug encapsulation (AIDE) platform. The technology involves harvesting a patient’s own red blood cells, adding dexamethasone sodium phosphate through the cells’ porous membranes, and using hypertonic solutions so the cells can encapsulate the drug for administration back into the patient. Dexamethasone is then expected to be slowly released into circulation. The goal is to reduce toxicity related to frequent high dose treatment with steroids, while maximizing drug exposure to maintain its anti-inflammatory effects.To test eDSP in A-T, Quinch launched the placebo-controlled phase 3 Neat study, which enrolled 105 patients, including 83 6- to 9-year-olds in the primary analysis population. Patients were given six infusions scheduled once every 21 to 30 days. The trial’s primary endpoint evaluated patients’ change from baseline to last efficacy visit at Month 6 using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) between eDSP and placebo.The study did not meet that endpoint, as the mean change was 0.94 for eDSP and 2.24 for placebo, with a p-value of 0.0851. A higher RmICARS score indicates greater disease severity of ataxia impairment.The study was powered at approximately 90% to test for a statistically significant difference between eDSP and placebo on the primary endpoint, Quince’s CEO and chief medical officer, Dirk Thye, M.D., said in the company’s third-quarter report in November. At that time, Thye expressed confidence in a successful readout, citing a go-ahead from an independent data monitoring committee following a safety analysis and all trial participants’ decision to enroll in an open-label extension study.On the trial’s secondary endpoint of improvement in Clinical Global Impression of Severity, also measured from baseline to Month 6, the p-value was 0.522, which, again, was not statistically significant.“eDSP was generally well tolerated and there were no clinically meaningful safety concerns identified,” Quince said. Neat was launched after another phase 3 trial, Attest, failed to show a benefit for Quince’s intra-erythrocyte approach in a wide age group. But a subgroup analysis found that children ages 6 to 9 years appeared to benefit from a high dose of the drug. In addition, the study authors also cited the pandemic as a possible reason for the flop, as many patients had delayed or missed treatments.

临床3期临床2期

2026-01-30

·GlobeNewswire-Health Care

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness. The investment is intended to support Quantum Scan’s ongoing efforts to identify, develop, and deploy innovative medical technologies, including advanced diagnostic platforms, integrated analytics, and scalable healthcare solutions designed to improve accessibility and efficiency across clinical and non-traditional care settings. Scilex believes this strategic investment is synergistic with its large investment in Datavault AI (Nasdaq: DVLT) (“Datavault”). Mustaq Patel, Chief Executive Officer of Quantum Scan, stated: “We are grateful to Scilex for their strategic investment and confidence in our team and vision. The need for continued innovation in medical technologies has never been greater. This capital enables Quantum Scan to accelerate its focus on forward-looking healthcare solutions and to invest in technologies that we believe can deliver long-term value and meaningful impact across the healthcare ecosystem.” Henry Ji, Ph.D., Chairman and Chief Executive Officer of Scilex Holding Company, commented: “Quantum Scan is led by an experienced team with a clear focus on innovation, revenue-generation, disciplined execution, and potential large long-term value creation. We believe this investment complements Scilex’s strategic priorities and provides an opportunity to support the development of innovative medical technology platforms aligned with our broader commitment to advancing healthcare solutions.” For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. About Quantum Scan Holdings, Inc. Quantum Scan Holdings, Inc. is a medical technology and innovation company focused on the development and investment in advanced healthcare technologies. Quantum Scan’s activities include medical platforms, diagnostics, analytics, and related innovations aimed at enhancing healthcare delivery, accessibility, and clinical insight. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Quantum Scan’s prospects, plans and goals, Scilex’s intellectual property goals and processes, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, Quantum Scan’s business and Datavault’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and Quantum Scan and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: www.scilexholding.com SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc. All other trademarks are the property of their respective owners. © 2026 Scilex Holding Company All Rights Reserved.

上市批准快速通道临床3期临床2期

2026-01-30

·国家药品监督管理局

2026年01月30日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CXHS2400029盐酸普萘洛尔滴剂四川奥邦古得药业有限公司国药准字H202600072026年01月27日2CXSS2400100/CXSS2400107流感病毒亚单位疫苗江苏中慧元通生物科技股份有限公司国药准字S202600042026年01月27日3CXSS2400108人纤维蛋白原同路生物制药有限公司国药准字S202600072026年01月27日4CXSS2400121流感病毒裂解疫苗武汉生物制品研究所有限责任公司国药准字S202600052026年01月27日5CXSS2400122流感病毒裂解疫苗武汉生物制品研究所有限责任公司国药准字S202600062026年01月27日6CXSS2400129埃诺格鲁肽注射液杭州先为达生物科技股份有限公司国药准字S202600082026年01月27日7CXZS2400038济川煎颗粒合肥华润神鹿药业有限公司国药准字C202600022026年01月27日8CYHS2302665依巴斯汀口服溶液广西维威制药有限公司国药准字H202632752026年01月27日9CYHS2303023萘普生钠片长春海悦药业股份有限公司国药准字H202631962026年01月27日10CYHS2400257克唑替尼胶囊昆山龙灯瑞迪制药有限公司国药准字H202632392026年01月27日11CYHS2400258克唑替尼胶囊昆山龙灯瑞迪制药有限公司国药准字H202632402026年01月27日12CYHS2400482加替沙星滴眼液合肥利民制药有限公司国药准字H202631972026年01月27日13CYHS2400654米诺地尔搽剂药大制药有限公司国药准字H202632762026年01月27日14CYHS2400743尼莫地平注射液山东华铂凯盛生物科技有限公司国药准字H202632492026年01月27日15CYHS2400758琥珀酸地文拉法辛缓释片扬子江药业集团有限公司国药准字H202632412026年01月27日16CYHS2400759琥珀酸地文拉法辛缓释片扬子江药业集团有限公司国药准字H202632422026年01月27日17CYHS2400785蒙脱石混悬液国药控股星鲨制药(厦门)有限公司国药准字H202631982026年01月27日18CYHS2400981盐酸克林霉素棕榈酸酯颗粒海南海神同洲制药有限公司国药准字H202631872026年01月27日19CYHS2401011钠钾镁钙注射用浓溶液华夏生生药业（北京）有限公司国药准字H202632772026年01月27日20CYHS2401063米诺地尔搽剂杭州端本医药科技有限公司国药准字H202632782026年01月27日21CYHS2401064米诺地尔搽剂杭州端本医药科技有限公司国药准字H202632792026年01月27日22CYHS2401128蛋白琥珀酸铁口服溶液哈药集团中药二厂国药准字H202632502026年01月27日23CYHS2401165阿立哌唑口服溶液昆明南疆制药有限公司国药准字H202632512026年01月27日24CYHS2401167阿立哌唑口服溶液昆明南疆制药有限公司国药准字H202632522026年01月27日25CYHS2401168阿立哌唑口服溶液昆明南疆制药有限公司国药准字H202632532026年01月27日26CYHS2401211甲氧氯普胺片浙江赛默制药有限公司国药准字H202632252026年01月27日27CYHS2401212甲氧氯普胺片浙江赛默制药有限公司国药准字H202632262026年01月27日28CYHS2401330达比加群酯胶囊天方药业有限公司国药准字H202631992026年01月27日29CYHS2401331达比加群酯胶囊天方药业有限公司国药准字H202632002026年01月27日30CYHS2401529二硫化硒洗剂安徽省先锋制药有限公司国药准字H202632802026年01月27日31CYHS2401573盐酸甲氧氯普胺注射液北京民康百草医药科技有限公司国药准字H202631882026年01月27日32CYHS2401627夫西地酸乳膏浙江百代医药科技有限公司国药准字H202632062026年01月27日33CYHS2401632维生素K₁注射液合肥亿帆生物制药有限公司国药准字H202632432026年01月27日34CYHS2401634氯化钙注射液河北千康医药科技有限责任公司国药准字H202632542026年01月27日35CYHS2401705盐酸甲氧氯普胺注射液嘉实（湖南）医药科技有限公司国药准字H202632012026年01月27日36CYHS2401755氯维地平乳状注射液石药集团中诺药业（石家庄）有限公司国药准字H202632272026年01月27日37CYHS2401756氯维地平乳状注射液石药集团中诺药业（石家庄）有限公司国药准字H202632282026年01月27日38CYHS2401811阿仑膦酸钠口服溶液广州一品红制药有限公司国药准字H202632552026年01月27日39CYHS2401812西格列汀二甲双胍缓释片常州制药厂有限公司国药准字H202632562026年01月27日40CYHS2401821阿法骨化醇软胶囊东海制药（河北）有限公司国药准字H202632442026年01月27日41CYHS2401876二甲双胍维格列汀片(II)仁合益康集团有限公司国药准字H202632292026年01月27日42CYHS2401904甲硝唑凝胶湖南及正医药科技有限公司国药准字H202631892026年01月27日43CYHS2401934硫辛酸片江苏万禾制药有限公司国药准字H202632302026年01月27日44CYHS2401935硫辛酸片江苏万禾制药有限公司国药准字H202632312026年01月27日45CYHS2401947富马酸伏诺拉生片广东东阳光药业股份有限公司国药准字H202632322026年01月27日46CYHS2401948富马酸伏诺拉生片广东东阳光药业股份有限公司国药准字H202632332026年01月27日47CYHS2402115盐酸普罗帕酮注射液石家庄四药有限公司国药准字H202632572026年01月27日48CYHS2402133地塞米松磷酸钠注射液安徽美来药业股份有限公司国药准字H202631902026年01月27日49CYHS2402234布瑞哌唑口崩片齐鲁制药有限公司国药准字H202632582026年01月27日50CYHS2402235布瑞哌唑口崩片齐鲁制药有限公司国药准字H202632592026年01月27日51CYHS2402236布瑞哌唑口崩片齐鲁制药有限公司国药准字H202632602026年01月27日52CYHS2402256、CYHB2500201盐酸莫西沙星滴眼液宏越科技（湖州）有限公司国药准字H202632812026年01月27日53CYHS2402258盐酸莫西沙星滴眼液宏越科技（湖州）有限公司国药准字H202632822026年01月27日54CYHS2402266盐酸布比卡因注射液广州合和医药有限公司国药准字H202632612026年01月27日55CYHS2402267盐酸布比卡因注射液广州合和医药有限公司国药准字H202632622026年01月27日56CYHS2402354乳果糖口服溶液浙江远力健药业有限责任公司国药准字H202632022026年01月27日57CYHS2402372依帕司他片宁夏康亚药业股份有限公司国药准字H202632072026年01月27日58CYHS2402393维生素B₁₂滴眼液江苏福邦药业有限公司国药准字H202632082026年01月27日59CYHS2402427盐酸溴己新口服溶液海南斯达制药有限公司国药准字H202632832026年01月27日60CYHS2402428盐酸溴己新口服溶液海南斯达制药有限公司国药准字H202632842026年01月27日61CYHS2402452注射用头孢他啶阿维巴坦钠湘北威尔曼制药股份有限公司国药准字H202631912026年01月27日62CYHS2402462铝碳酸镁咀嚼片四川依科制药有限公司国药准字H202632092026年01月27日63CYHS2402468依托泊苷注射液成都瑞尔医药科技有限公司国药准字H202632452026年01月27日64CYHS2402503盐酸肾上腺素注射液河南润弘制药股份有限公司国药准字H202631922026年01月27日65CYHS2402526吡格列酮二甲双胍片（Ⅰ）南京易亨制药有限公司国药准字H202632632026年01月27日66CYHS2402553铝碳酸镁咀嚼片海南海神同洲制药有限公司国药准字H202632102026年01月27日67CYHS2402582注射用头孢哌酮钠舒巴坦钠湘北威尔曼制药股份有限公司国药准字H202632112026年01月27日68CYHS2402583注射用头孢哌酮钠舒巴坦钠湘北威尔曼制药股份有限公司国药准字H202632122026年01月27日69CYHS2402584注射用头孢哌酮钠舒巴坦钠湘北威尔曼制药股份有限公司国药准字H202632132026年01月27日70CYHS2402585氯化钙注射液湖南埃威格林医药科技有限公司国药准字H202632642026年01月27日71CYHS2402596头孢托仑匹酯片福安药业集团庆余堂制药有限公司国药准字H202632342026年01月27日72CYHS2402600达格列净片山西德元堂药业有限公司国药准字H202632032026年01月27日73CYHS2402601达格列净片山西德元堂药业有限公司国药准字H202632042026年01月27日74CYHS2402609硫代硫酸钠注射液四川上善六经医药科技有限公司国药准字H202632652026年01月27日75CYHS2402610硫代硫酸钠注射液四川上善六经医药科技有限公司国药准字H202632662026年01月27日76CYHS2402636甲磺酸艾立布林注射液海南倍特药业有限公司国药准字H202632352026年01月27日77CYHS2402654玛巴洛沙韦片浙江普利药业有限公司国药准字H202632852026年01月27日78CYHS2402655玛巴洛沙韦片浙江普利药业有限公司国药准字H202632862026年01月27日79CYHS2402656盐酸利多卡因凝胶江苏联环药业股份有限公司国药准字H202631932026年01月27日80CYHS2402665拉考沙胺注射液北京海步医药科技有限公司国药准字H202632142026年01月27日81CYHS2402755盐酸曲唑酮片四川科伦药业股份有限公司国药准字H202632462026年01月27日82CYHS2402756盐酸曲唑酮片四川科伦药业股份有限公司国药准字H202632472026年01月27日83CYHS2402762富马酸伏诺拉生片苏州中化药品工业有限公司国药准字H202631942026年01月27日84CYHS2402895硫酸镁钠钾口服用浓溶液广东隆赋药业股份有限公司国药准字H202632152026年01月27日85CYHS2402913盐酸达泊西汀片安徽省先锋制药有限公司国药准字H202632362026年01月27日86CYHS2402944奥美沙坦酯口崩片江西施美药业股份有限公司国药准字H202631952026年01月27日87CYHS2402948达格列净片郑州泰丰制药有限公司国药准字H202632162026年01月27日88CYHS2402949达格列净片郑州泰丰制药有限公司国药准字H202632172026年01月27日89CYHS2403039硝酸异山梨酯注射液济南康桥医药科技有限公司国药准字H202632672026年01月27日90CYHS2403101卡左双多巴缓释片江苏和晨药业有限公司国药准字H202632182026年01月27日91CYHS2403177氯化钙注射液湖南科伦制药有限公司国药准字H202632682026年01月27日92CYHS2403178氯化钙注射液湖南科伦制药有限公司国药准字H202632692026年01月27日93CYHS2403287吗啉硝唑氯化钠注射液四川美大康佳乐药业有限公司国药准字H202632702026年01月27日94CYHS2403303盐酸氨溴索口服溶液白云山汤阴东泰药业有限责任公司国药准字H202632192026年01月27日95CYHS2403350替米沙坦氨氯地平片苏州东瑞制药有限公司国药准字H202632202026年01月27日96CYHS2403397恩格列净片郑州泰丰制药有限公司国药准字H202632712026年01月27日97CYHS2403398恩格列净片郑州泰丰制药有限公司国药准字H202632722026年01月27日98CYHS2403416富马酸伏诺拉生片天地恒一制药股份有限公司国药准字H202632482026年01月27日99CYHS2403431、CYHB2502327硫酸氨基葡萄糖胶囊四川贝灵合益制药有限公司国药准字H202632212026年01月27日100CYHS2403603平衡盐溶液（供灌注用）河北天成药业股份有限公司国药准字H202632372026年01月27日101CYHS2403826氟伐他汀钠缓释片杭州泓友医药科技有限公司国药准字H202632872026年01月27日102CYHS2403841艾拉莫德片海南合瑞制药股份有限公司国药准字H202632052026年01月27日103CYHS2403843地屈孕酮片新疆特丰药业股份有限公司国药准字H202632222026年01月27日104CYHS2403890阿昔莫司胶囊江苏谦仁生物科技有限公司国药准字H202632232026年01月27日105CYHS2403997地夸磷索钠滴眼液深圳市宇健生物医药有限公司国药准字H202632242026年01月27日106CYHS2404022布洛芬混悬液武汉九珑医药有限责任公司国药准字H202632382026年01月27日107CYHS2404079硫酸氢氯吡格雷片辽宁鑫善源药业有限公司国药准字H202632882026年01月27日108CYHS2501320氧榆林市榆阳区聚源氧气厂国药准字H202632732026年01月27日109CYHS2501326氧安康市汉滨区秦安气体制售中心国药准字H202632742026年01月27日110JXHS2400036环磷酰胺片百特医疗仪器设备（上海）有限公司国药准字HJ202600192026年01月27日111JXHS2400073磷酸芦可替尼乳膏海南德镁医药科技有限责任公司国药准字HJ202600182026年01月27日112JXHS2400120、JXHB2500107硫酸艾沙康唑胶囊辉瑞投资有限公司国药准字HJ202600172026年01月27日113JXHS2400122马昔腾坦他达拉非片（II）强生制药有限公司国药准字HJ202600152026年01月27日114JXHS2400123马昔腾坦他达拉非片（I）强生制药有限公司国药准字HJ202600162026年01月27日115JXHS2500043英克司兰钠注射液北京诺华制药有限公司国药准字HJ202301032026年01月27日116JXHS2500081甲磺酸洛美他派胶囊凯西医药咨询（上海）有限公司国药准字HJ202600122026年01月27日117JXHS2500082甲磺酸洛美他派胶囊凯西医药咨询（上海）有限公司国药准字HJ202600132026年01月27日118JXHS2500083甲磺酸洛美他派胶囊凯西医药咨询（上海）有限公司国药准字HJ202600142026年01月27日

疫苗申请上市高管变更

100 项与地塞米松磷酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00975	地塞米松磷酸钠	D07AB19 H02AB02 D10AA03	DB01234

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑水肿	奥地利	Hameln pharma Gmbh.	2021-04-28
脑水肿	比利时	Hameln pharma Gmbh.	2021-04-28
脑水肿	保加利亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	克罗地亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	捷克	Hameln pharma Gmbh.	2021-04-28
脑水肿	丹麦	Hameln pharma Gmbh.	2021-04-28
脑水肿	芬兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	德国	Hameln pharma Gmbh.	2021-04-28
脑水肿	匈牙利	Hameln pharma Gmbh.	2021-04-28
脑水肿	冰岛	Hameln pharma Gmbh.	2021-04-28
脑水肿	爱尔兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	意大利	Hameln pharma Gmbh.	2021-04-28
脑水肿	荷兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	挪威	Hameln pharma Gmbh.	2021-04-28
脑水肿	波兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	葡萄牙	Hameln pharma Gmbh.	2021-04-28
脑水肿	罗马尼亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛伐克	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛文尼亚	Hameln pharma Gmbh.	2021-04-28
新型冠状病毒感染	奥地利	Hameln pharma Gmbh.	2021-04-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	美国	TLC BioSciences	2019-11-26
膝关节炎	临床3期	美国	台湾微脂体股份有限公司	2019-11-26
膝关节炎	临床3期	澳大利亚	TLC BioSciences	2019-11-26
膝关节炎	临床3期	澳大利亚	台湾微脂体股份有限公司	2019-11-26
根性疼痛	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
神经根病	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
共济失调毛细血管扩张	临床3期	美国	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	澳大利亚	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	比利时	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	德国	Quince Therapeutics, Inc.	2017-03-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02389517 (CTgov)	临床2期	多发性骨髓瘤 \| 残留肿瘤	42	Lenalidomide+Ixazomib Citrate+Dexamethasone (Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone))	觸糧築獵願艱觸鹽繭餘 = 廠選鹹膚鬱鑰繭製製簾壓糧鹽艱構糧獵鑰繭選 (構築窪襯窪網繭鏇願蓋, 艱顧築遞蓋願鬱遞膚鏇 ~ 窪鑰艱獵鏇齋範襯獵製) 更多	-	2026-01-22
				Lenalidomide (Arm II (Lenalidomide))	觸糧築獵願艱觸鹽繭餘 = 築襯簾繭鏇製膚遞膚顧壓糧鹽艱構糧獵鑰繭選 (構築窪襯窪網繭鏇願蓋, 顧艱襯選積蓋鹹鹽鏇顧 ~ 餘齋衊廠淵糧襯憲築窪) 更多
NCT06006624 (Pubmed \| Orthop J Sports Med)	临床4期	-	131	Liposomal bupivacaine	觸範膚鏇糧選糧衊餘鹽(鹹糧夢糧餘膚壓觸顧顧) = 網鹹繭蓋壓膚積衊遞構憲顧積膚衊蓋憲齋廠淵 (範糧醖鬱鹽鹽廠餘醖醖, 21.9)	积极	2026-01-01
				Liposomal bupivacaine + dexamethasone	觸範膚鏇糧選糧衊餘鹽(鹹糧夢糧餘膚壓觸顧顧) = 繭網艱醖積遞淵蓋鑰窪憲顧積膚衊蓋憲齋廠淵 (範糧醖鬱鹽鹽廠餘醖醖, 14.33)
NCT03389620 (CTgov)	临床2期	神经根病	74	dexamethasone (Transforaminal Cervical Epidural Corticosteroid Injections)	餘簾壓構齋膚蓋積醖獵(鹽鹽窪淵遞遞憲壓鑰窪) = 願蓋衊壓鏇選蓋選鹹憲顧夢壓鹹鹹膚廠夢鑰選 (選廠築獵製觸網簾構鑰, 2.50) 更多	-	2025-12-19
				dexamethasone (Lateralized Interlaminar Epidural Corticosteroid Injections)	餘簾壓構齋膚蓋積醖獵(鹽鹽窪淵遞遞憲壓鑰窪) = 網糧積鏇襯艱糧鬱製衊顧夢壓鹹鹹膚廠夢鑰選 (選廠築獵製觸網簾構鑰, 2.20) 更多
ASH2025	N/A	多发性骨髓瘤一线	1,721	CD38 Antibody, Immunomodulator, Proteasome Inhibitor, and Dexamethasone	壓網鹽夢顧選鹹壓齋選(鑰醖構鬱鏇壓選蓋鑰憲) = 鹹糧築願艱繭繭繭餘築蓋鏇蓋製選簾鏇構簾鹹 (鬱廠醖艱網獵範襯襯夢 ) 更多	不佳	2025-12-06
ASH2025	N/A	非霍奇金淋巴瘤	44	Dexamethasone prophylaxis	夢鏇遞網遞積簾壓築積(選襯鏇夢窪廠簾憲簾願) = 願顧衊築願窪範壓鹹繭範獵淵窪築壓鏇襯簾齋 (窪鏇襯夢積衊膚醖夢壓 ) 更多	积极	2025-12-06
				No dexamethasone prophylaxis	夢鏇遞網遞積簾壓築積(選襯鏇夢窪廠簾憲簾願) = 鏇醖壓範遞鏇餘齋積製範獵淵窪築壓鏇襯簾齋 (窪鏇襯夢積衊膚醖夢壓 ) 更多
ASH2025	N/A	免疫性血小板减少症一线	226	Dexamethasone 40 mg daily for 4 days with additional courses as needed	鏇遞獵選壓繭獵網蓋壓(顧壓窪淵衊構淵夢醖製) = 膚願築淵壓膚壓壓鏇餘鏇製膚膚醖襯願製顧壓 (醖鹹艱艱鑰範鏇鹽選醖, 27.3 ~ 47.9) 更多	不佳	2025-12-06
				Prednisone with tapering down	鏇遞獵選壓繭獵網蓋壓(顧壓窪淵衊構淵夢醖製) = 鑰獵遞獵窪襯範網憲網鏇製膚膚醖襯願製顧壓 (醖鹹艱艱鑰範鏇鹽選醖, 6.8 ~ 18.7) 更多
ECWM-1 (ASH2025)	N/A	巨球蛋白血症一线	204	Bortezomib + Dexamethasone + Rituximab + Cyclophosphamide	衊積夢簾網鏇廠製鑰廠(齋鏇製廠繭衊齋夢觸艱) = Grade≥3 toxicities were mainly hematological 獵餘膚積壓夢鏇顧簾醖 (憲鏇遞鹹廠願鹹糧網窪 ) 更多	积极	2025-12-06
				Dexamethasone + Rituximab + Cyclophosphamide
ASH2025	临床1/2期	t(11;14)	12	Venetoclax ± Dexamethasone	積壓鬱醖築衊遞網窪範(齋糧網廠繭艱鬱範醖願) = only one patient that developed grade 3 infection (lung infection; COVID-19) 觸淵鹽餘淵醖醖廠鹹齋 (襯淵簾膚廠鹽鑰顧選選 ) 更多	积极	2025-12-06
ChiCTR2200064695 (ASH2025)	临床2期	肾功能不全一线	63	Selinexor + Pomalidomide + Bortezomib + Dexamethasone	鹽獵簾鹽齋觸艱醖衊築(範製鹹構築憲膚糧憲蓋) = 齋艱醖醖願艱壓壓簾膚醖襯範糧簾積憲鏇鹽蓋 (選觸網蓋壓餘製廠鏇獵 ) 更多	积极	2025-12-06
ASH2025	N/A	免疫球蛋白轻链淀粉样变性	9	Daratumumab+ Pomalidomide +Dexamethasone	選遞憲製齋餘鑰顧壓築(繭憲糧廠衊蓋範鹽膚願) = neutropenia in 3 patients (without associated infections) and anemia in 1 patient. 鹹積醖鬱艱壓夢鏇蓋築 (蓋積齋蓋衊積鏇餘衊獵 ) 更多	积极	2025-12-06